{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-037139","form_type":"8-K","ticker":null,"cik":"0001845459","company_name":"NKGen Biotech, Inc.","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.738854+00:00","generated_at":"2026-06-03T05:44:28.852397+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NKGen amends warrants to $2.00, defers repayment on $550K notes","bullets":["Amended and restated 8.2M warrants: cashless conversion delayed, exercise price reset to $2.00/share.","Entered letter agreements with Meteora and Sandia on $550K notes to defer repayment right until Excess Proceeds exceed $10M.","Paid $116K cash, issued 416,667 shares, and 550,000 warrants at $2.00 to noteholders.","Warrants to noteholders have 5-year term."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-037139","json":"https://secwatch.observer/filing/0001213900-24-037139.json","markdown":"https://secwatch.observer/filing/0001213900-24-037139.md","text":"https://secwatch.observer/filing/0001213900-24-037139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024037139/0001213900-24-037139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024037139/ea0204784-8k_nkgen.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:44:28.852397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28d5506e3935f8686838688abe383a72bad680ed","claim":"NKGen Biotech, Inc. entered into Sandia Letter with Sandia Investment Management LP valued at agreed not to exercise Repayment Right until Excess Proceeds exceed $10 million in total; Company to (effective 2024-04-28).","evidence_excerpt":"On April 28, 2024, the Company entered into letter agreements with each of Meteora (the \" Meteora Letter \") and Sandia (the \" Sandia Letter \" and together with the Meteora Letter, the \" Letters \") in connection with the Notes.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024037139/0001213900-24-037139-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Sandia Investment Management LP"},{"label":"Value","value":"agreed not to exercise Repayment Right until Excess Proceeds exceed $10 million in total; Company to"},{"label":"Effective","value":"2024-04-28"}],"fact_type":"material_agreement"},{"claim_id":"9f06565f982c7112b3797e5e349cd6bbd5c2b4b4","claim":"NKGen Biotech, Inc. amended AR Subscribed Warrants with certain investors valued at exercise price reset to $2.00 per share (effective 2024-04-25).","evidence_excerpt":"On April 25, 2024, the Company amended and restated the Subscribed Warrants, (the \" AR Subscribed Warrants \"). Among other things, the AR Subscribed Warrants: (i) delay the Investor’s right to convert the Subscribed Warrants on a cashless basis and (ii) reset and cap the exercise price to $2.00 per share for all Subscribed Warrants.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024037139/0001213900-24-037139-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"exercise price reset to $2.00 per share"},{"label":"Effective","value":"2024-04-25"}],"fact_type":"material_agreement"},{"claim_id":"ba52f116b7637251847cbb5182b96100d274e758","claim":"NKGen Biotech, Inc. entered into Meteora Letter with Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Capital, LLC valued at agreed not to exercise Repayment Right until Excess Proceeds exceed $10 million in total; Company to (effective 2024-04-28).","evidence_excerpt":"On April 28, 2024, the Company entered into letter agreements with each of Meteora (the \" Meteora Letter \") and Sandia (the \" Sandia Letter \" and together with the Meteora Letter, the \" Letters \") in connection with the Notes.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024037139/0001213900-24-037139-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Capital, LLC"},{"label":"Value","value":"agreed not to exercise Repayment Right until Excess Proceeds exceed $10 million in total; Company to"},{"label":"Effective","value":"2024-04-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}